Profile image
By marketresearchnest
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

Clostridium Difficile Infections Therapeutics Pipeline Market H1 2017

Thursday, May 18, 2017 4:03
% of readers think this story is Fact. Add your two cents.

(Before It's News) adds “Clostridium Difficile Infections – Pipeline Review, H1 2017” new report to its research database. The report spread across in multiple pages with table and figures in it.


Latest Pharmaceutical and Healthcare disease pipeline guide Clostridium difficile Infections – Pipeline Review, H1 2017, provides an overview of the Clostridium difficile Infections (Infectious Disease) pipeline landscape.

Clostridium difficile infections are caused by Clostridium difficile, often called C. difficile or C. diff, a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Symptoms of C. diff infection includes watery diarrhea, with abdominal pain or tenderness, loss of appetite, fever, blood or pus in the stool and weight loss. Risk factors are age, surgery of the gastrointestinal (GI) tract, a weakened immune system, kidney disease, use of drugs called proton-pump inhibitors, which lessen stomach acid and use of chemotherapy drugs. This condition may be controlled by the use of medication such as antibiotics and may be prevented by lifestyle modification.

Browse full table of contents and data tables at

The Clostridium difficile Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Clostridium difficile Infections (Clostridium difficile Associated Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 9, 11, 29, 15 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 7 molecules, respectively.

Clostridium difficile Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.


Clostridium Difficile Infections – Companies Involved in Therapeutics Development

Absynth Biologics Ltd

Actelion Ltd

AIMM Therapeutics BV

Akthelia Pharmaceuticals Ltd

AmpliPhi Biosciences Corp

Appili Therapeutics

Assembly Biosciences Inc

AvidBiotics Corp

C3J Therapeutics Inc

CaroGen Corp

Crestone Inc

Da Volterra SAS

Daiichi Sankyo Company Ltd

Evec Inc

GangaGen Inc

ImmunoBiology Ltd

Immuron Ltd

Inovio Pharmaceuticals Inc

Integrated BioTherapeutics Inc

Merck & Co Inc

MGB Biopharma Ltd

Microbiotix Inc

Micropharm Ltd

Miyarisan Pharmaceutical Company Ltd

Nabriva Therapeutics AG

Nanotherapeutics Inc

Novabiotics Ltd

NovoBiotic Pharmaceuticals LLC

Oragenics Inc

Otsuka Holdings Co Ltd

Pfizer Inc

Prokarium Ltd

Rebiotix Inc

Sanofi Pasteur SA

Second Genome Inc

Seres Therapeutics Inc

Serometrix LLC

Sorrento Therapeutics Inc

Summit Therapeutics Plc

Synthetic Biologics Inc

Valevia UK Ltd

Valneva SE

XBiotech Inc


Order a Purchase Report Copy at


Scope of this Report

- The pipeline guide provides a snapshot of the global therapeutic landscape of Clostridium difficile Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Clostridium difficile Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Clostridium difficile Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Clostridium difficile Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Clostridium difficile Infections (Infectious Disease)


Request Sample Copy at


About Us:                  is the most comprehensive collection of market research products and services on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on global industries, organizations, products, and trends.


Contact Us

Mr. Jeet Jain

Sales Manager

[email protected]


Connect with us:  Google+ | LinkedIn | Twitter | Facebook

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global


Top Alternative




Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.